Jan 01,2019

Changing Health Raises £3 million For New Behaviour Change Programmes

Changing Health, a leading provider of digital behaviour change programmes, has secured £3 million in new funding. The round was led by Shift Invest from the Netherlands, together with renewed investment from existing backers, Tate & Lyle Ventures and the North East Innovation Fund supported by the European Regional Development Fund, and managed by Northstar Ventures.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 03,2019

Tandem Diabetes Care Announces Appointment of Rebecca Robertson as Board Member

“Beckie has an impressive track-record of helping medical device companies scale in her roles as an engineer, entrepreneur, corporate executive and board member,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “Her experience with a diverse range of technologies and business models, combined with her strategic vision, further strengthens our Board as we prepare for the Company’s next phase of growth.”

View Analyst & Ambassador Comments
Go to original news
Jan 03,2019

New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health

Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (NYSE:IBM) Watson Health, today announced a new feature for the Sugar.IQ personal diabetes assistant app called IQcast(TM). Using artificial intelligence (AI) technology from IBM Watson Health, the feature aims to predict the likelihood of an individual experiencing a low glucose event within an upcoming 1-4 hour window.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 07,2019

Insulet Appoints Wayde McMillan Chief Financial Officer

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Wayde McMillan has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2019, succeeding Michael Levitz. To ensure a smooth and successful transition, Mr. McMillan will join the Company in February and Mr. Levitz will continue with the Company in an advisory capacity for a period following the succession effective date.

View Analyst & Ambassador Comments
Go to original news
Jan 07,2019

Fit4D Changes Name to Cecelia Health and Expands Mission Beyond Diabetes

Fit4D Inc., a leading technology-enabled diabetes and chronic disease management company based in New York City, announced today at the 2019 Startup Health Festival that it has changed its name to Cecelia Health. This new company name reflects the company’s mission to transform the lives and health outcomes of people living with diabetes and related chronic diseases, and leverage Cecelia Health’s unique data-driven insights gained from its personalized coaching platform to optimize health outcomes at an affordable cost.

View Analyst & Ambassador Comments
Go to original news
Jan 08,2019

POCTech announced the establishment of global strategic collaboration relationship with Ascensia Diabetes Care

On January 8th 2019, Zhejiang POCTech Co., Led（POCTech） announced plans to cooperate with Ascensia Diabetes Care (ADC) on global multi-regional sales and to joint develop next generation of Continuous Glucose Monitoring (CGM) system. POCTech has reached agreements with Ascensia that appoint Ascensia to act as the sole distributor in 13 countries which POCTech has untapped. Meanwhile, Ascensia has the priority to be the exclusive agent of POCTech’s untapped markets. As a part of agreements, Ascensia will start to sell and promote POCTech’s CE certified CGM product (CT-100B) from mid-2019.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 08,2019

New Roche Study Uses Real-World Data to Predict Diabetes-related Chronic Kidney Disease

Chronic kidney disease is one of the most severe secondary complications related to diabetes. A study demonstrates new predictive model based on real-world data to offer enhanced accuracy compared to traditional methods in prognosing the risk of this diabetes-related long-term complication

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jan 08,2019

Cecelia Health Partners with JCHR and the Helmsley Trust To Transform the Lives and Health Outcomes of People Living with Diabetes

Cecelia Health, a leading diabetes management technology- enabled personalized diabetes coaching company based in New York City, announced today it has partnered with The Jaeb Center for Health Research (JCHR) to pilot a study to remotely onboard and support people using Continuous Glucose Monitors (CGM). The study is funded by The Leona M. and Harry B. Helmsley Charitable Trust.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 12,2019

Integration of Ketone Sensing into Closed Loop Systems: The Clinical Case

Closed loop (CL) systems deliver insulin with a rapid onset and offset in action. Although favorable overall, the absence of a long-acting insulin increases the risk of diabetic ketoacidosis (DKA) which can occur with insulin delivery failure, acute illness, low carbohydrate diets, sodium glucose-linked transporter inhibitors, and high intensity exercise. A CL system relying entirely on interstitial glucose measurements may not provide an alert for DKA and many people with type 1 diabetes (T1D) do not carry a blood ketone meter and test-strips.

CLINICAL STUDY

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 15,2019

Cecelia Health Partners with Valeritas to Support Success of Innovative V-Go Wearable Insulin Delivery Device Designed for People Living with Diabetes

Cecelia Health a leading diabetes management technology-enabled personalized coaching company based in New York City, announced today it is partnering with Valeritas, to support the success of V-Go, an innovative wearable insulin delivery device for people living with diabetes who require insulin. Cecelia Health Certified Diabetes Educators (CDEs) will support people living with diabetes with both their initial use of V-Go as well as their ongoing use of V-Go to help them achieve improved results with their diabetes management. V-Go is an insulin delivery option for people with diabetes who require insulin that is worn like a patch and can replace the need to take multiple daily shots.

COLLABORATION PARTNERSHIP

#product & service

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES